EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Treatment with Sulodexide Downregulates Biomarkers for Endothelial Dysfunction in Convalescent COVID-19 Patients

Alejandro J Gonzalez-Ochoa iD, Gyozo Szolnoky iD, Ana G Hernandez-Ibarra, Jawed Fareed iD

Clinical and Applied Thrombosis/Hemostasis · 2025-01 · 31

DOI: 10.1177/10760296241297647 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Applied Thrombosis/Hemostasis, online erschienen am 07.01.2025. Verfasst von Alejandro J Gonzalez-Ochoa und 3 weiteren Autor:innen. Beteiligte Einrichtung: Vascular Surgery Department, Centro Médico del Noroeste, San Luis Rio Colorado, Sonora, México. Hauptthemen laut MEDLINE: Biomarkers, COVID-19, COVID-19 Drug Treatment, Endothelium, Vascular. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Alfasigma SpA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Persistent elevation of biomarkers associated with endothelial dysfunction in convalescent COVID-19 patients has been linked to an increased risk of long-term cardiovascular complications, including long COVID syndrome. Sulodexide, known for its vascular endothelial affinity, has demonstrated pleiotropic protective properties. This study aims to evaluate the impact of sulodexide on serum levels of endothelial dysfunction biomarkers in patients during the convalescent phase of COVID-19.

Methods

We conducted a double-blind, single-center, randomized, placebo-controlled trial in Mexico, comparing sulodexide (250 LRU orally, twice daily) with placebo over 8 weeks in adult patients during early COVID-19 convalescence. Differences in serum biomarkers between the groups were analyzed using repeated measures and post hoc tests, with Thrombomodulin (TM) as the primary endpoint.

Results

Among 206 analyzed patients (103 in each group), at week 8, the sulodexide group exhibited significantly lower mean levels of Thrombomodulin (TM) (25.2 ± 7.9 ng/mL vs 29.9 ± 14.7 ng/mL, P = .03), von Willebrand Factor (vWF) (232 ± 131 U/dL vs 266 ± 122 U/dL, P = .02) and Interleukin-6 (IL-6) (12.5 ± 13.2 pg/mL vs 16.2 ± 16.5 pg/mL, P = .03) compared to the placebo group. D-dimer and C reactive protein (CRP) in the sulodexide group were also lowered. No significant differences were observed for P-selectin, fibrinogen, VCAM-1, or ICAM-1 levels.

Conclusions

Patients in the convalescent phase of COVID-19 who received sulodexide for eight weeks showed a reduction in TM, vWF, D-dimer, CRP, and IL-6 serum levels compared to placebo. These findings suggest a potential protective effect of sulodexide against thromboinflammation and endothelial damage.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiomarkersCOVID-19COVID-19 Drug TreatmentEndothelium, VascularGlycosaminoglycansThrombomodulinAdultAgedFemaleHumansMaleMiddle AgedC-Reactive ProteinConvalescenceDouble-Blind MethodDown-RegulationFibrin Fibrinogen Degradation ProductsInterleukin-6Mexico

Stichwörter der Autor:innen

convalescent COVID-19endothelial dysfunctioninflammationlong COVID-19sulodexidethrombomodulin

Substanzen

BiomarkersC-Reactive ProteinFibrin Fibrinogen Degradation Productsfibrin fragment Dglucuronyl glucosamine glycan sulfateGlycosaminoglycansInterleukin-6THBD protein, humanThrombomodulin

Autor:innen und Institutionen

  • Vascular Surgery Department, Centro Médico del Noroeste, San Luis Rio Colorado, Sonora, México.
  • Vascular and Endovascular Surgery department, CLINEDEM, San Luis Rio Colorado, Sonora, México.
  • Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
  • Otorhinolaryngology department, CLINEDEM, San Luis Rio Colorado, Sonora, México.
  • Hemostasis and Thrombosis Research Laboratories, Loyola University Medical Center, Maywood, Illinois, USA.

ORCID-Profile: Alejandro J Gonzalez-Ochoa, Gyozo Szolnoky, Jawed Fareed

Förderung

  • Alfasigma SpA

Zitieren

APA

Gonzalez-Ochoa, A. J., Szolnoky, G., Hernandez-Ibarra, A. G., & Fareed, J. (2025). Treatment with Sulodexide Downregulates Biomarkers for Endothelial Dysfunction in Convalescent COVID-19 Patients. Clinical and Applied Thrombosis/Hemostasis, 31. https://doi.org/10.1177/10760296241297647

Vancouver

Gonzalez-Ochoa AJ, Szolnoky G, Hernandez-Ibarra AG, Fareed J. Treatment with Sulodexide Downregulates Biomarkers for Endothelial Dysfunction in Convalescent COVID-19 Patients. Clinical and Applied Thrombosis/Hemostasis. 2025;31. doi:10.1177/10760296241297647

BibTeX
@article{GonzalezOchoa2025,
  author = {Gonzalez-Ochoa, Alejandro J and Szolnoky, Gyozo and Hernandez-Ibarra, Ana G and Fareed, Jawed},
  title = {Treatment with Sulodexide Downregulates Biomarkers for Endothelial Dysfunction in Convalescent COVID-19 Patients},
  journal = {Clinical and Applied Thrombosis/Hemostasis},
  year = {2025},
  volume = {31},
  doi = {10.1177/10760296241297647}
}
Kostenlos starten →